In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 301 to 325 of 361

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]	Technology appraisal guidance	TBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC
Surgical vessel sealing systems (MT798)	Medical technologies guidance	TBC
Suspected Cancer: recognition and referral (update)	NICE guideline	13 March 2026
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	19 November 2025
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	TBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	15 October 2025
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]	Technology appraisal guidance	15 October 2025
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]	Technology appraisal guidance	17 December 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]	Technology appraisal guidance	6 August 2025
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance	TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	TBC
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	13 August 2025
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance	TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753	Technology appraisal guidance	25 June 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	TBC
Tolebrutinib for treating secondary progressive multiple sclerosis ID6351	Technology appraisal guidance	TBC

Results per page

10
25
50
All